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We investigated themechanismof action, safety, and efficacy of the Site-Specific Immunomodulator (SSI)QBECO, a novel immuno-
therapy forCrohn’s disease (CD).Using humanmonocytic THP-1 cells, we demonstrate that SSIQBECO (derived from the common
colon bacteria E. coli) activates macrophages to an M1 phenotype (associated with enhanced capacity to eliminate bacteria and
activate innate immune responses). We assessed SSI QBECO in a compassionate use protocol of ten adult patients with active CD.
Patients with moderate to severe clinical symptoms receiving conventional CD treatments and/or complementary therapies were
included, except patients receiving anti-TNF medications. SSI QBECO was self-administered subcutaneously every second day,
for a minimum of 2.5 months and a maximum of 11 months. All 10 patients reported improvement of symptoms while on the SSI
QBECO treatment. Seven patients reported full resolution of clinical symptoms during a course of SSI QBECO of at least three
months. Three patients have experienced ongoing sustained clinical remission after discontinuing all medications, including SSI
treatment.The longest case of clinical remission is still ongoing (>4 years). No serious severe adverse clinical events were reported.
Collectively, we conclude that treatmentwith the immunoactive SSIQBECOwaswell tolerated and effective for treatment ofCrohn’s
disease in this case series.
1. Introduction
Crohn’s disease (CD) is a relapsing gastrointestinal inflamma-
tory disorder [1] that results in 40–55% of patients requiring
disease-related abdominal surgery within 10 years of diagno-
sis and a postoperative relapse rate of 44–55% after 10 years
[2]. CD patients are also at increased risk for small bowel
and colorectal cancers [3]. Its incidence is increasing amongst
most ethnic groups [1, 4]. No curative treatment currently
exists, and the effects of the long-term use of immunosup-
pressants and other medications used to treat its symptoms
are poorly understood [2]. Moreover, because few, if any,
experimental models of CD accurately resemble the human
illness [1, 5, 6], the development of effective bench-to-bedside
treatments is “increasingly difficult” [1].
Site-Specific Immunomodulators (SSIs) are a new and
novel platform of immunotherapies created by Qu Biologics
(QB) that may transcend this bench-to-bedside experimental
impasse. SSIs are complex biologics designed to activate an
innate immune response in a targeted, organ-specificmanner
and are each derived from a single species of inactivated
bacteria that is a common cause of acute infection in the tar-
geted organ. SSIs reverse the innate immune dysfunction
and chronic inflammation that underlies both cancer and
immune-mediated diseases, including CD, by stimulating
the recruitment of a new wave of activated innate immune
cells and the removal of the chronic source of unproductive
inflammation.
The aims of this study were to (1) establish a con-
ceptual framework for SSI mechanism of action using the
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gut-targeting drug SSI QBECO and (2) summarize the clini-
cal and safety data for SSI QBECO in a case series from the
compassionate-use program in patients with active CD. It
has been suggested previously [5, 7–9] that impaired macro-
phage functionality plays a key role in the propagation of
inflammation in CD by inhibiting the normal removal of
damaged or infected cells and bacteria from the gut mucosa.
Our central hypothesis was that by restoring normal macro-
phage functionality within the gut microenvironment of
active CD patients through the administration of the SSI
QBECO, we would effectively treat CD. These data form the
precedent for a Phase 1/2 randomized, placebo-controlled,
double-blind clinical trial that is currently evaluating the
efficacy and safety of SSI QBECO in patients with moderate-
to-severe CD.
2. Materials and Methods
2.1. SSI QBECO Drug Product Preparation. SSI QBECO,
derived from an inactivated enteropathic strain of E. coli, was
suspended in physiological saline containing 0.4% phenol as
preservative. SSI QBECO was designed to target activated
macrophage recruitment to the gastrointestinal tract, where
enteropathic E. coli typically causes infection.
2.2. Human Monocytic Cell Line THP-1 Cell Culture. THP-
1 cells were maintained in RPMI with L-glutamine (Fisher)
supplemented with 50 𝜇M 2ME (Sigma Aldrich) and 10%
FBS (Fisher). When ready to culture, cells were seeded at
2 × 10
6/mL in 96- or 24-well tissue culture plates. PMA
(200 ng/mL, Sigma-Aldrich) was added overnight to trigger
differentiation to macrophages. After 20 hours (hrs), PMA
media were removed and cells were washed twice in supple-
mented media.
2.3. Cytokine Dose Response Analysis. THP-1 cells were cul-
tured with either LPS (used as a positive control) from E. coli
(serotype 0111:B4 Sigma Aldrich, 0.01−10𝜇g/mL) or with SSI
QBECO (5OD at 1 : 20, 1 : 200, 1 : 500, or 1 : 2500 dilutions)
for 18 hrs, after which supernatants were removed and frozen
for later analysis. Cytokine levels were quantified by specific
ELISA for TNF-𝛼 and IL-1𝛽 (R&D Systems DuoSets). The
limits of detection were 15.6 pg/mL and 3.91 pg/mL, respec-
tively.
2.4. THP-1 Polarization. THP-1 cells were cultured in the
presence of media for M0, IFN𝛾 (20 ng/mL, Peprotech) and
LPS (100 ng/mL) forM1, or IL-4 and IL-13 (both at 20 ng/mL,
Peprotech) for M2 or with SSI QBECO drug product (1 : 20
or 1 : 500). After 18 hrs, RNAwas extracted from cell pellets of
polarized THP-1 cells using a PureLinkRNAMini Kit accord-
ing to manufacturer’s instructions (Ambion, Life Technolo-
gies). Genomic DNA was removed and cDNA was synthe-
sized from 100 ng RNA using QuantiTect Reverse Transcrip-
tion Kit (Qiagen). Real time PCR was performed with Taq-
man Fast Advanced Master Mix (Applied Biosystems) in the
presence of 6-carboxyfluorescein- (FAM-) labeled primers
for M1 genes (CCL19, CXCL11, CCR7, and TNF) and M2
genes (CCL13, CCL18, and FGL) (Applied Biosystems) using
a StepOnePlus instrument (Applied Biosystems). Amplifica-
tion conditions were 95∘C for 20 seconds (s), 95∘ for 1 s before
60∘C for 20 s for 40 cycles. Expression of M1 and M2 genes
was normalized to 18SRNA (Applied Biosystems) for quan-
tification. The housekeeping gene CT value was subtracted
from the gene of interest CT (ΔCT). The difference was then
calculated between the control (M2) and the other samples
(ΔΔCT). The fold change was then calculated from this
number (2(−ΔΔCT)).
2.5. Patients. Ten CD subjects between 24 and 44 years of
age with moderate to severe clinical symptoms of active CD
refractory to current treatments received the SSI QBECO
according to a compassionate-use protocol (Table 1). Subjects
receiving conventional CD treatments and/or complemen-
tary therapies were included; subjects receiving anti-TNF
medications were excluded.
2.6. Informed Consent. Between July 2010 and January 2013,
patients who had failed standard treatments for CD were,
at the discretion of the treating physician, eligible for the
compassionate-use of experimental treatments inAustria and
The Bahamas. Signed patient informed consent was obtained
from all patients prior to initiation of SSI QBECO treatment.
Treatment of patients, according to a submitted protocol for
SSI QBECO use, was approved by Bahamas Clinical Services
for the eight patients treated in the Bahamas. The two CD
patients enrolled in Austria were treated under the Austrian
Named Patient Use Program (http://www.basg.gv.at/filead-
min/user upload/L I217 Compassionate use AT en.pdf), con-
sistent with prior reports [11]. The Bahamian and Austrian
compassionate use programs were conducted in accordance
with the 1975 Helsinki Declaration, as revised in 2008.
2.7. Treatment. Patients were taught to self-administer SSI
QBECO treatment by subcutaneous injection every second
day. Beginning with a dose of 0.05mL, the dose was gradually
increased (by 0.02mL) until a 2.5–5.0 cm light pink local
skin immune response (LSIR) was obtained as measured on
the day following the injection, indicating the achievement
of an adequate LSIR. Once this LSIR was achieved (or the
maximum dose of 0.2mL was reached), this customized dose
was continued every second day until the end of the treatment
course (minimumof 2.5months to amaximumof 11months).
Dose, dose frequency, and side-effects were captured daily in
a subject diary, and subjects were followed up closely by a
physician (authorKevin P. Bethel or Ralf Kleef) who regularly
assessed their adverse events and clinical symptoms of CD.
Response and remission were assessed by the treating physi-
cian and were determined based on the physician’s overall
assessment of each patient’s CD during the course of therapy.
Assessments were made by office visit or by telephone
consultation.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: SSI QBECO- and LPS-induced cytokine release in THP-1 cells. THP-1 cells were activated overnight with PMA, then stimulated
with diluted SSI QBECO (1 : 2500–1 : 20 dilution, (a)-(b)) or LPS (0.01–10𝜇g/mL) for 18 hrs. Supernatants were removed and TNF-𝛼 ((a), (c))
or IL-1𝛽 ((b), (d)) was assessed by specific ELISA. Data are means ± standard deviation of triplicate assessments from one of three similar
experiments.
3. Results
3.1. Preclinical: SSI QBECO Induced M1-Skewed Responses
in the THP-1 Monocyte Cell Line. We assessed the capacity
for SSI QBECO to induce macrophage cytokine and gene
expression in vitro, using the humanmonocytic cell lineTHP-
1. SSI QBECO treatment of THP-1 cells, following activation
to macrophage phenotype by overnight culture with PMA,
induced the production of proinflammatory, M1-associated
cytokines (IL-1𝛽 and TNF-𝛼, Figure 1) in a dose-dependent
manner that resembles LPS-activated cytokine production.
Further, SSI QBECO induced the expression of a panel of
M1-associated, but not M2-associated [12], gene products
(Figure 2). These data demonstrate that SSI QBECO prefer-
entially induces the M1-type differentiation of macrophages.
This observation provides, in part, a rationale for the evalua-
tion of SSI QBECO in patients with chronic active CD.
3.2. Clinical: Compassionate-Use Clinical Program Patient
Response. Thepatient demographics are described in Table 1.
Patient 5 had a history of a rectovaginal fistula; at the time of


































ECO 1 : 20
ECO 1 : 500
Figure 2: M1 and M2 mRNA expression in polarized THP-1 cells.
THP-1 cells were cultured for 18 hrs with IFN𝛾 and LPS (generating
an M1 phenotype), IL-4 and IL-13 (generating an M2 phenotype),
or SSI QBECO (1 : 20 or 1 : 500 dilution). Specific gene expression of
M1- (CCL19, CXCL11, CCR7, and TNF-𝛼) and M2- (CCL13, CCL18,
and FGL1) associated genes was quantified by qPCR. Data are fold
change in gene expression, relative to M2 polarized cells.
receiving SSI therapy, she had no symptoms related to this
pathology. Patient 5 received SSI therapy for treatment of her
Gastroenterology Research and Practice 5
Table 2: Patient response to SSI QBECO treatment.
Patient QBECO SSItherapy duration
Response while





1 11 months Remission Ongoing remission 3.8years None Colonoscopy
2 3 months Remission Ongoing remission 2.8years None CT scan







5 3.5 months Remission Remission 1.2 years,disease recurrence Standard care n/a
6 5 months Remission Remission 3 months,disease recurrence Standard care n/a
7 7.5 months Remission Recurrence post-SSILess severe symptoms Standard care n/a





Symptom return post-SSI Standard care n/a
10 2.5 months Improvement Symptom return post-SSI Standard care n/a
Standard care: patient is being treated by other approved CD drugs.
luminal symptoms. Patient 5 did not respond to 5ASA, and
no other medical therapies were tried prior to SSI treatment.
Ten of 10 patients reported improvement of symptoms
while on SSI QBECO treatment. Seven patients reported
full resolution of clinical symptoms during a course of SSI
QBECO treatment of at least three months. Three patients
have experienced ongoing sustained clinical remission after
discontinuing all medications, including SSI treatment. The
longest case of clinical remission reported is still ongoing,
after more than four years. All three patients have had a fol-
low-up colonoscopy or CT scan with confirmation of remis-
sion of CD (Table 2).
3.3. Adverse Events. With a maximum follow-up period of
52 months, no treatment-related serious adverse events have
been observed or reported to date. The only reported treat-
ment-related adverse events were 2-3 episodes of transient
fever lasting 12–24 hrs in three patients (which resolved with-
out treatment within 12–24 hrs) and a larger than anticipated
transient local skin immune response to initial treatment
dose in one patient, which was corrected with appropriate
dose reduction.
4. Discussion
While CD is an immune-mediated disease, it is not an auto-
immune disease [7, 13].The CD immunodeficiency hypothesis
(IDH), dating in part to the late 1970s [14], asserts that (1)
infectious agents breach the bowel mucosal lining, (2) a pre-
disposing innate immune deficiency prompts an ineffective
acute physiological inflammation and impaired recruitment
of phagocytes, (3) the neutrophil-based phagocytes become
overwhelmed, (4) macrophages therefore attempt to contain
the pathogens but are less capable at this function, and (5)
these macrophages drive a chronic but inefficient immune
response [5] (Figure 3(a)). This hypothesis was perceived to
be in conflict with the apparent clinical efficacy of immuno-
suppressive medications used to treat CD symptoms and its
popularity waned. However, new supporting IDH evidence
[5, 6, 9, 15, 16] suggests that there are, in fact, several discreet
phases of immunodeficient responses in CD: the first involv-
ing poor cytokine production by resident tissuemacrophages
followed by diminished neutrophil recruitment and subse-
quent chronic inflammation [16]. Indeed, it is this compen-
satory chronic inflammation response that is suppressed by
medications such as azathioprine, infliximab, and adali-
mumab (which have been the focus of current CD treatment).
By extension, treatment of the deficient first acute innate
immune response could also address the subsequent ineffi-
cient inflammation phase that results in clinicalmanifestation
ofCDand thereby potentially reduce or eliminate the need for
the long-term use of immunosuppressive medications in CD
patients. SSIs initiate such a response, one that is innate, acute,
functional, organ-specific, and nontoxic to the tissue inwhich
the respective bacterial species commonly causes infection
(Figure 3(b)). In preclinical models, the SSI QBECO specif-
ically targets the gut and we have demonstrated that it stim-
ulates innate immune responses in the colon and gastroin-
testinal tract (unpublished observation). Since macrophage
defect or deficiency, in particular, may be the underlying









Pre-SSI: predominance of immune-suppressive macrophages,




























SSI treatment: recruitment of immune-supportive macrophages
Submucosa
(b)
Figure 3: Proposedmodel of SSI-mediatedM1macrophage accumulation and effector function in CD. (a) Pre-SSI microenvironment of CD,
with predominance of dysfunctional macrophages and unresolved infection/chronic inflammation from lack of initial acute inflammatory
response. (b) Post-SSI microenvironment, with recruited immune-supportive M1 macrophages capable of clearing the bacteria that initiate
acute inflammatory responses and pave the way for M2 macrophages to engage in healing and rebuilding activities.
trigger forCD, the SSIQBECOwas designed to induce organ-
specific macrophage recruitment and activation, resulting in
the clearance of bacterial infection and necrotic debris.
The deficiency observed in the first innate mucosal
immune response in CD patients may be that of defective M1
macrophages, and the resultant inflammation phase of clin-
ical symptoms may be caused by the accumulation of other
dysfunctional (potentially M2) macrophages concurrently
with the unresolved infection. While M2 macrophages lead
to tissue regeneration and repair [17], they are incapable of
either killing/removing bacteria or instigating an effective
innate immune response, which is the hallmark ofM1macro-
phages. This ultimately Sisyphean effort leads to cyclic, but
futile, attempts at repair with the simultaneous ineffective
clearance of the initial infection. Thus, we hypothesized that
the SSI QBECO, which drives M1 macrophage polarization
in vitro, may also drive M1 expansion in patients and thereby
lead to more effective treatment of the underlying cause of
CD, and not just its symptoms. By extension, once the under-
lying source of inflammation was cleared, the symptoms
characteristic of CD would resolve in patients who received
the SSI QBECO medication. We observed clinical remission
during administration of the SSI QBECO in a compassion-
ate-use context in seven of 10 patients who had moderate to
severe clinical symptoms of active CD at baseline, with the
remaining three of 10 noting improvement of their symptoms
during treatment. Three of the 10 patients have experienced
ongoing long-term remission. Based on these initial findings,
and the recognized limitations of compassionate-use stud-
ies regarding causal attribution and mechanism of action,
induction of clinical response and remission by SSI QBECO
therapy is now being evaluated through a Phase 1/2 ran-
domized, placebo-controlled, double-blind clinical trial. QB
is currently characterizing the unique qualities of SSI-stim-
ulatedM1macrophage populations, and, in future studies,QB
will explore the potentially unique genetic differences of the
Gastroenterology Research and Practice 7
long-term responder cohort in order to develop assays that
would identify, a priori, likely future candidates for which
treatment would be efficacious and warranted.
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